The results of a key Alzheimer s drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.
Lecanemab was found to slow the progress of Alzheimer s by a quarter - putting an end to decades of failed trials. It has reignited hopes targeting amyloid beta plaque is the key to treating the disease.
Analysis-Alzheimer s drug breakthrough big boost for Roche, Eli Lilly gazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazette.com Daily Mail and Mail on Sunday newspapers.